Teva says gluten challenge study succeeds in celiac disease
A single injection of an experimental antibody significantly reduced intestinal damage among people with celiac disease who then ate gluten daily, Teva Pharmaceuticals said Wednesday. The Israeli drugmaking giant reported topline ...
September 2, 2026 10:58 AM EDT R&D Teva reports a single-shot success in celiac disease, heating the IL-15 market Andrew Dunn Senior Biopharma Correspondent A single injection of an experimental antibody significantly reduced intestinal damage among people with celiac disease who then ate gluten daily, Teva Pharmaceuticals said Wednesday. … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that